Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 19Neoplasm Metastasis 17Colorectal Neoplasms 17Ovarian Neoplasms 15Lymphoma, Non-Hodgkin 15Carcinoma, Renal Cell 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Myelodysplastic Syndromes 11Lung Neoplasms 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Adenocarcinoma 9Thyroid Neoplasms 8

Interventions

pexidartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has announcements × Synovitis, Pigmented Villonodular × Clear all
NCT05059262 2026-03-20

MOTION

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
123 enrolled 19 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02371369 2022-05-11

ENLIVEN

Daiichi Sankyo

Phase 3 Completed
120 enrolled 25 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡